1. Home
  2. RVMDW vs DPZ Comparison

RVMDW vs DPZ Comparison

Compare RVMDW & DPZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • DPZ
  • Stock Information
  • Founded
  • RVMDW N/A
  • DPZ 1960
  • Country
  • RVMDW United States
  • DPZ United States
  • Employees
  • RVMDW 490
  • DPZ N/A
  • Industry
  • RVMDW
  • DPZ Food Distributors
  • Sector
  • RVMDW
  • DPZ Consumer Discretionary
  • Exchange
  • RVMDW Nasdaq
  • DPZ Nasdaq
  • Market Cap
  • RVMDW N/A
  • DPZ N/A
  • IPO Year
  • RVMDW N/A
  • DPZ 2004
  • Fundamental
  • Price
  • RVMDW $0.20
  • DPZ $442.39
  • Analyst Decision
  • RVMDW
  • DPZ Buy
  • Analyst Count
  • RVMDW 0
  • DPZ 28
  • Target Price
  • RVMDW N/A
  • DPZ $501.46
  • AVG Volume (30 Days)
  • RVMDW N/A
  • DPZ 495.1K
  • Earning Date
  • RVMDW N/A
  • DPZ 02-24-2025
  • Dividend Yield
  • RVMDW N/A
  • DPZ 1.37%
  • EPS Growth
  • RVMDW N/A
  • DPZ 11.23
  • EPS
  • RVMDW N/A
  • DPZ 16.28
  • Revenue
  • RVMDW N/A
  • DPZ $4,665,474,000.00
  • Revenue This Year
  • RVMDW N/A
  • DPZ $7.02
  • Revenue Next Year
  • RVMDW N/A
  • DPZ $6.05
  • P/E Ratio
  • RVMDW N/A
  • DPZ $27.16
  • Revenue Growth
  • RVMDW N/A
  • DPZ 4.41
  • 52 Week Low
  • RVMDW N/A
  • DPZ $396.06
  • 52 Week High
  • RVMDW N/A
  • DPZ $542.75
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • DPZ 55.52
  • Support Level
  • RVMDW N/A
  • DPZ $409.70
  • Resistance Level
  • RVMDW N/A
  • DPZ $445.61
  • Average True Range (ATR)
  • RVMDW 0.00
  • DPZ 10.83
  • MACD
  • RVMDW 0.00
  • DPZ 3.59
  • Stochastic Oscillator
  • RVMDW 0.00
  • DPZ 86.76

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: